Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia

MI  Ying-chang; LI  Min-ming

doi:10.12019/j.issn.1671-5144.2017.02.004

MI Ying-chang, LI Min-ming. Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2017.02.004

Citation:

MI Ying-chang, LI Min-ming. Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2017.02.004

Citation:

MI Ying-chang, LI Min-ming. Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia[J]. Journal of Evidence-Based Medicine, 2017, 17(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2017.02.004

Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia

Graphical Abstract

Abstract

FullText(HTML)

References (6)

Efficacy and Tolerability of Sorafenib for Patients of Younger and Newly Diagnosed Acute Myeloid Leukemia

Catalog

Export File

Citation

Format

Content